Aardvark Therapeutics, Inc. (AARD) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US0029421007
Price
1.44 USD
Market cap
31.51 m USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–
Aardvark Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 0.00 USD |
| Operating income | -62.73 m USD |
| EBIT | -62.73 m USD |
| Net income | -57.59 m USD |
| Diluted EPS – continuing operations | -2.93 USD |
Full history since 2022, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Aardvark Therapeutics, Inc.
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
More stocks
- Kestrel Group Ltd (KG)
- Grandstand Limited (GRSD)
- NextCure, Inc. (NXTC)
- Zhanling International Ltd (ZLME)
- Pelthos Therapeutics Inc. (PTHS)
- Bluerock Homes Trust, Inc. (BHM)
- RAPID MICRO BIOSYSTEMS, INC. (RPID)
- COFFEE HOLDING CO INC (JVA)
- ISTE Co., Ltd. (212710.KQ)
- Holistic Asset Finance Group Co., Ltd. (HAFG)
- SCANDIUM INTERNATIONAL MINING CORP. (SCYYF)
- MARIMED INC. (MRMD)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.